Trafalgar International, Inc.
- Filings
- 145
- Raw facts
- 5,432
- Metric values
- 1,300
FY 2021−73.7% FY21 yoy
Q2 2026N/M FY25 yoy
Q2 2026N/M FY25 yoy
—
—
—Q2 2026
Q2 2026−38.2% FY23 yoy
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2021 | 2021-12-31 | $12,630 | reported | |
| FY 2020 | 2020-12-31 | $48,044 | reported | |
| FY 2019 | 2019-12-31 | $7,120 revised | reported | |
| FY 2018 | 2018-12-31 | $95,375 | reported | |
| FY 2017 | 2017-12-31 | $209 | reported |
Segments
Products
LineFY2021ShareChange
Product$12.63K100%−73.7%
Consulting Fees———
Total$12.63K
Pharmaceutical preparations
Trafalgar International, Inc. is the 496th largest of the 553 covered companies the SEC files under this code, by total assets. SIC 2834
CompanyRevenueGrowthNet marginAssets
BIXTBioxytran, Inc———$333.4KRGBPRegen BioPharma Inc$236.6K0.0%538.8%$287.6KSKVISkinvisible, Inc.$20.0K0.0%5,320.2%$123.3KBDPTBioadaptives, Inc.$18.3K44.3%8,523.4%$78.8KCTTHCTT Pharmaceutical Holdings, Inc.Fiscal 2014 figures———$67.4KZOARZoar Ltd———$23.8KCNBXCNBX Pharmaceuticals Inc.$0.0100.0%—$12.8KNIKANika Pharmaceuticals, Inc———$5.3K
TRFATrafalgar International, Inc. (this company)———$111.0
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in total assets first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Trafalgar International, Inc. · CIK 1695473 · Engraved from SEC EDGAR